Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biochemotherapy for advanced melanoma.

Ulrich Keilholz1, Martin E Gore

  • 1Department of Medicine III (Hematology, Oncology, and Transfusion Medicine), University Hospital Benjamin Franklin, Free University of Berlin, Berlin, Germany.

Seminars in Oncology
|October 31, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targetable alterations and personalized treatment in ameloblastoma: results from a prospective observational precision oncology study.

NPJ precision oncology·2026
Same author

Clinically actionable genomic and transcriptomic landscape of advanced neuroendocrine neoplasms.

Med (New York, N.Y.)·2026
Same author

Liquid biopsy-based detection of acquired MET resistance enables sequential targeted therapy in MET fusion-positive NSCLC.

The oncologist·2026
Same author

Impact of culture dimensionality and matrix composition on morphology, phenotype and drug response in pancreatic cancer models.

Scientific reports·2026
Same author

Comprehensive molecular analyses for diagnosis and treatment guidance in an adult neuroblastoma patient.

The oncologist·2026
Same author

ADC Target Profiling in NSCLC: Generalizable AI Separates TROP-2 and cMET Phenotypes.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Biochemotherapy, combining interleukin-2 (IL-2) and interferon alpha (IFN-alpha) with chemotherapy, shows promise for advanced melanoma. While durable responses are rare with chemotherapy alone, these novel treatments offer improved response rates in clinical trials.

Area of Science:

  • Oncology
  • Immunotherapy
  • Melanoma Research

Background:

  • Chemotherapy for stage IV melanoma yields unsatisfactory outcomes with limited durable responses.
  • Experimental treatments like vaccines and gene therapy have shown limited efficacy in advanced melanoma patients.

Purpose of the Study:

  • To evaluate the efficacy of biotherapy and biochemotherapy as first-line treatments for stage IV melanoma.
  • To compare biochemotherapy regimens with biotherapy alone and chemotherapy in randomized trials.

Main Methods:

  • Review of various interleukin-2 (IL-2) dosing schedules and combinations with interferon alpha (IFN-alpha).
  • Evaluation of biochemotherapy regimens combining IL-2, IFN-alpha, and chemotherapy in phase II trials.
  • Analysis of recent randomized trials comparing biochemotherapy to biotherapy or chemotherapy.

Related Experiment Videos

Main Results:

  • IL-2, alone or with IFN-alpha, shows response rates from 10% to 41%, including durable responses.
  • Biochemotherapy regimens suggest improved response rates compared to biotherapy alone.
  • No current approach has definitively proven a survival benefit in advanced melanoma.

Conclusions:

  • Biochemotherapy is a preferred first-line treatment for stage IV melanoma due to observed response rates.
  • Further research and inclusion in controlled clinical trials are necessary to establish survival benefits.
  • Developing effective treatments for advanced melanoma remains a critical area of research.